EMX1 and hepatocellular carcinoma: Besides, higher expression of EMX1 indicated shorter overall survival (P = 0.011, TCGA-LIHC cohort, Fig. 1I) and recurrence-free survival (P = 0.011, SYSUCC cohort 1, Supplementary Fig. S1N) in early-stage HCC subgroup.